LA
Lilly Asia Ventures
Venture CapitalActiveLilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical
87
Investments
5
Exits
$3B
AUM
5.7%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Lilly Asia Ventures.
Investment Thesis & Strategy
Lilly Asia Ventures invests in various stages of biotech and healthcare companies in Asia, seeking innovative pharmaceutical companies.
Investment Activity
Deals per year over the last 7 years
4
20110
20120
20133
20143
20151
20161
2017Portfolio Companies
Selected investments from their portfolio of 87 companies
A
Adagene
Biotech · Growth, 2017
H
Harbour BioMed
Biotech · Growth, 2016
H
Hansoh Pharmaceutical
Biotech · Growth, 2015
C
CanSino Biologics
Biotech · Growth, 2015
I
I-Mab
Biotech · Growth, 2015
L
Legend Biotech
Biotech · Growth, 2014
B
BeiGene
Biotech · Growth, 2014
Z
Zai Lab
Biotech · Growth, 2014
W
Wuxi Biologics
Biotech · Growth, 2011
E
Epizyme
Biotech · Series B, 2011
H
Hua Medicine
Biotech · Growth, 2011
I
Innovent Biologics
Biotech · Growth, 2011
Notable Exits
CompanyTypeYearValue / Acquirer
Legend BiotechIPO2020$3.5B
I-MabIPO2020$221M
Innovent BiologicsIPO2018$3.3B
Zai LabIPO2017$1.1B
BeiGeneIPO2016$750M
Frequently Asked Questions
Lilly Asia Ventures focuses on Series A, Series B, Series C+ stage investments.